Sanofi

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines, vaccines franchises, support, and corporate functions 1973 and is headquartered in Paris, France. 

CEO
Belén Garijo López
CEOBelén Garijo López
Employees
76,493
Employees76,493
Headquarters
Paris, Ile-de-France
HeadquartersParis, Ile-de-France
Founded
1973
Founded1973
Employees
76,493
Employees76,493

SNY Key Statistics

Market cap
114.02B
Market cap114.02B
Price-Earnings ratio
24.38
Price-Earnings ratio24.38
Dividend yield
3.71%
Dividend yield3.71%
Average volume
3.42M
Average volume3.42M
High today
$47.76
High today$47.76
Low today
$46.63
Low today$46.63
Open price
$47.41
Open price$47.41
Volume
2.32M
Volume2.32M
52 Week high
$50.94
52 Week high$50.94
52 Week low
$39.07
52 Week low$39.07

SNY News

Seeking Alpha 3h
Sanofi wins approval of venglustat for Gaucher disease

Sanofi wins approval of venglustat for Gaucher disease Nov 18, 2026, 5:43 PM ET Sanofi (SNY) Stock SAN:CA By : Jonathan Block, SA News Editor The US FDA approve...

Sanofi wins approval of venglustat for Gaucher disease
TipRanks 5h
FDA approves Genzyme’s Infilbray tablets for Gaucher disease treatment

The U.S. Food and Drug Administration approved Infilbray tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease in adults and pedi...

Simply Wall St 4d
How Investors Are Reacting To Nurix Therapeutics CMO Appointment

Nurix Therapeutics appointed Arati V. Rao, M.D. as chief medical officer and reported that partner Sanofi ended the SAR448272 STAT6 degrader program, removing a...

How Investors Are Reacting To Nurix Therapeutics CMO Appointment

Analyst ratings

60%

of 10 ratings
Buy
60%
Hold
40%
Sell
0%

More SNY News

TipRanks 4d
Sanofi Earnings Call Signals Growth Despite Pipeline Risks

Sanofi SA ((SNY)) has held its Q3 earnings call. Read on for the main highlights of the call. Sanofi’s third-quarter earnings call carried a strongly positive...

Simply Wall St 5d
Nurix Therapeutics Could Be 55% Undervalued After Sanofi Ends Phase 1 Program

Nurix Therapeutics (NRIX) shares are in focus after Sanofi ended its Phase 1 trial for SAR448272, which cuts off potential milestones and royalties tied to that...

Nurix Therapeutics Could Be 55% Undervalued After Sanofi Ends Phase 1 Program
TipRanks 5d
Sanofi price target raised to EUR 93 from EUR 78 at Citi

Citi analyst Graham Parry raised the firm’s price target on Sanofi (SNY) to EUR 93 from EUR 78 and keeps a Neutral rating on the shares. Published first on The...

TipRanks 5d
Sanofi Updates Infant Pompe Disease Study: What Investors Should Know

Sanofi (SNYNF) announced an update on their ongoing clinical study. Study Overview: Sanofi’s study, officially titled “A Prospective Observational Study to Des...

The Wall Street Journal 6d
Health Care Roundup: Market Talk

george frey / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....

Health Care Roundup: Market Talk
TipRanks 6d
Sanofi Discloses October 31, 2026 Share and Voting Rights Figures

An update from Sanofi ( (FR:SAN) ) is now available. Sanofi, a French société anonyme with share capital of EUR 2,415,546,786, reported that on 31 October 2026...

TipRanks 6d
Sanofi Updates Long-Term Frexalimab Study as Investors Watch Multiple Sclerosis Pipeline

Sanofi SA (SNY) announced an update on their ongoing clinical study. Study Overview: Sanofi’s Phase 3 study, officially titled “A Phase 3 Extension Study to In...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.